{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Hepatitis+A+virus%2C+inactivated", "query": { "intervention": "Hepatitis A virus, inactivated" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 16, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Hepatitis+A+virus%2C+inactivated&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-30T10:36:54.469Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01779505", "title": "A Phase 1a Trial Assessing the Safety, Tolerability, and Immunogenicity of GS-4774 (GI-13020) at Various Dose Levels and Regimens in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "GS-4774", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2013-01", "completion_date": "2013-08", "has_results": false, "last_update_posted_date": "2014-01-08", "last_synced_at": "2026-09-30T10:36:54.469Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01779505" }, { "nct_id": "NCT03620162", "title": "A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pneumococcal Infections" ], "interventions": [ { "name": "Prevnar 13™", "type": "BIOLOGICAL" }, { "name": "V114", "type": "BIOLOGICAL" }, { "name": "RotaTeq™", "type": "BIOLOGICAL" }, { "name": "Pentacel™", "type": "BIOLOGICAL" }, { "name": "RECOMBIVAX HB™", "type": "BIOLOGICAL" }, { "name": "HIBERIX™", "type": "BIOLOGICAL" }, { "name": "M-M-R™ II", "type": "BIOLOGICAL" }, { "name": "VARIVAX™", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "42 Days", "maximum_age": "90 Days", "sex": "ALL", "summary": "42 Days to 90 Days" }, "enrollment_count": 900, "start_date": "2018-10-18", "completion_date": "2020-12-14", "has_results": true, "last_update_posted_date": "2023-01-17", "last_synced_at": "2026-09-30T10:36:54.469Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Jonesboro, Arkansas + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03620162" }, { "nct_id": "NCT00001078", "title": "A Study on the Rate of Opportunistic (AIDS-Related) Infections Among HIV-Positive Children Who Have Stopped Taking Their OI Preventive Medications", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Hepatitis A Vaccine (Inactivated)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 200, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2011-03-02", "last_synced_at": "2026-09-30T10:36:54.469Z", "location_count": 47, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001078" }, { "nct_id": "NCT00050921", "title": "Administration of Growth Hormone to Increase CD4+ Count in Patients Taking Anti-HIV Drugs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "somatropin", "type": "DRUG" }, { "name": "Hepatitis A virus, inactivated", "type": "BIOLOGICAL" }, { "name": "Keyhole-Limpet Hemocyanin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": null, "completion_date": "2005-03", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-09-30T10:36:54.469Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Los Angeles, California • Sacramento, California + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00050921" }, { "nct_id": "NCT01681992", "title": "Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Measles", "Mumps", "Rubella", "Measles-Mumps-Rubella Vaccine" ], "interventions": [ { "name": "Priorix", "type": "BIOLOGICAL" }, { "name": "M-M-R II", "type": "BIOLOGICAL" }, { "name": "Varivax", "type": "BIOLOGICAL" }, { "name": "Havrix", "type": "BIOLOGICAL" }, { "name": "Prevnar 13", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Months", "maximum_age": "15 Months", "sex": "ALL", "summary": "12 Months to 15 Months" }, "enrollment_count": 4538, "start_date": "2012-10-10", "completion_date": "2015-08-18", "has_results": true, "last_update_posted_date": "2021-01-07", "last_synced_at": "2026-09-30T10:36:54.469Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01681992" }, { "nct_id": "NCT04398706", "title": "Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pneumococcal Immunisation", "Diphtheria Immunisation", "Tetanus Immunisation", "Pertussis Immunisation", "Hepatitis B Immunisation", "Haemophilus Influenzae Type b Immunisation", "Polio Immunisation", "Measles Immunisation", "Rubella Immunisation", "Varicella Immunisation", "Mumps Immunisation" ], "interventions": [ { "name": "Pneumococcal Conjugate Vaccine formulation 1", "type": "BIOLOGICAL" }, { "name": "Pneumococcal Conjugate Vaccine formulation 2", "type": "BIOLOGICAL" }, { "name": "Pneumococcal Conjugate Vaccine formulation 3", "type": "BIOLOGICAL" }, { "name": "Varicella Virus Vaccine Live", "type": "BIOLOGICAL" }, { "name": "Measles, Mumps, and Rubella Virus Vaccine Live", "type": "BIOLOGICAL" }, { "name": "Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]", "type": "BIOLOGICAL" }, { "name": "Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)", "type": "BIOLOGICAL" }, { "name": "Rotavirus Vaccine, Live, Oral, Pentavalent", "type": "BIOLOGICAL" }, { "name": "Hepatitis B Vaccine* [Recombinant] *as applicable", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "42 Days", "maximum_age": "15 Months", "sex": "ALL", "summary": "42 Days to 15 Months" }, "enrollment_count": 852, "start_date": "2020-05-22", "completion_date": "2023-08-10", "has_results": true, "last_update_posted_date": "2025-09-08", "last_synced_at": "2026-09-30T10:36:54.469Z", "location_count": 49, "location_summary": "Jonesboro, Arkansas • Bellflower, California • Huntington Park, California + 41 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Bellflower", "state": "California" }, { "city": "Huntington Park", "state": "California" }, { "city": "Huntington Park", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04398706" }, { "nct_id": "NCT00124215", "title": "Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "GI-5005", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlobeImmune", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2005-06", "completion_date": "2010-02", "has_results": false, "last_update_posted_date": "2010-05-05", "last_synced_at": "2026-09-30T10:36:54.469Z", "location_count": 5, "location_summary": "Pasadena, California • Denver, Colorado • Miami, Florida + 2 more", "locations": [ { "city": "Pasadena", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00124215" }, { "nct_id": "NCT00004735", "title": "The Effects of Anti-HIV Therapy on the Immune Systems of Children and Young Adults Infected With HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Tetanus toxoid", "type": "BIOLOGICAL" }, { "name": "Hepatitis A Vaccine (Inactivated)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "24 Years", "sex": "ALL", "summary": "2 Years to 24 Years" }, "enrollment_count": 81, "start_date": "2000-02", "completion_date": "2006-09", "has_results": false, "last_update_posted_date": "2013-10-07", "last_synced_at": "2026-09-30T10:36:54.469Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Alhambra, California • Long Beach, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Alhambra", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004735" }, { "nct_id": "NCT00505063", "title": "Prospective Trial of Vaccine Responses in Childhood Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Childhood Cancer", "Multiple Diseases" ], "interventions": [ { "name": "Immunization Schedule patients <7 years.", "type": "BIOLOGICAL" }, { "name": "Immunization Schedule patients > or = to 7 years and <11 years of age", "type": "BIOLOGICAL" }, { "name": "Immunization Schedule patients > or = to 11 years of age", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "2 Years to 18 Years" }, "enrollment_count": 75, "start_date": "2007-07-10", "completion_date": "2025-06-11", "has_results": true, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-09-30T10:36:54.469Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00505063" }, { "nct_id": "NCT00606086", "title": "Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Genotype 1 Chronic Hepatitis C" ], "interventions": [ { "name": "GI-5005", "type": "DRUG" }, { "name": "Pegylated Interferon and Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlobeImmune", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2007-12", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2014-06-27", "last_synced_at": "2026-09-30T10:36:54.469Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00606086" } ] }